Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.

Neoadjuvant FOLFIRINOX, chemoradiotherapy improve pancreatic cancer surgery outcomes

08 Aug 2018

Treatment with a neoadjuvant regimen containing fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) followed by individualized chemoradiotherapy for borderline resectable pancreatic cancer leads to high margin-negative (R0) resection rate, which translates to longer survival, according to the results of a single-arm phase II trial.

The trial enrolled 48 treatment-naïve patients (median age 62 years; 56.3 percent male) who had ECOG performance status of 1–0 and adequate haematologic, renal and hepatic function. Forty-three received eight cycles of FOLFIRINOX. Those who showed resolution of vascular involvement underwent short-course chemoradiotherapy (5 Gy) with capecitabine, while those with persistent vascular involvement underwent long-course treatment with fluorouracil or capecitabine.

Of the patients who planned to receive eight preoperative cycles of chemotherapy, 34 (79 percent) completed treatment. Twenty-seven (56 percent) had short-course chemoradiotherapy, while 17 (35 percent) received long course. Nearly all the 32 patients who underwent resection achieved R0 (97 percent).

In the entire cohort, median progression-free survival (PFS) was 14.7 months (95 percent CI, 10.5–not reached) while median overall survival was 37.7 months (19.4–not reached). The respective 2-year PFS and OS were 43 percent and 56 percent.

In the group of patients who underwent resection, median PFS was 48.6 months while median OS had not been reached. The corresponding 2-year PFS and OS were 55 percent and 72 percent.

Neoadjuvant FOLFIRINOX followed by chemoradiotherapy had a favourable toxicity profile, with no single grade 3 toxicity exceeding 10 percent and no toxic effect resulting in death.

The median follow-up for the analysis was 18.0 months for the 30 patients still alive at study completion.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.